MedTrace Logo

Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease

NCT01978587 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2014-03-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of hemodialysis on the pharmacokinetics (PK) of JTZ-951 and to evaluate the safety of 2 doses of JTZ-951 in subjects with end-stage renal disease (ESRD) receiving hemodialysis

Conditions

  • Anemia in Chronic Kidney Disease

Interventions

DRUG

JTZ-951

Sponsors & Collaborators

  • Akros Pharma Inc.

    lead INDUSTRY

Principal Investigators

  • Hideyuki Yamamoto · Akros Pharma Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2013-12-31
Completion
2014-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01978587 on ClinicalTrials.gov